MedGenome launches OncoTrack MRD to transform personalised cancer care in India

Advancing a new frontier in precision cancer care, MedGenome, India’s leading genomics‑driven diagnostics and research services company, has announced the launch of OncoTrack MRD, a personalised and Ultrasensitive NGS-based tumour‑informed Molecular Residual Disease (MRD) test.

The test was unveiled at an event in Bengaluru, by leading oncologists Dr Niti Raizada, Dr Vinayak Maka, and Dr Rajeev Vijayakumar, along with Ramprasad Vedam, PhD, CEO, MedGenome Labs.

The experts came together to discuss advancements in personalised cancer care in India, the importance of earlier detection of cancer relapse and the role of molecular monitoring in cancer care.

MedGenome’s OncoTrackMRD is a comprehensive, personalised, tumour-informed, molecular residual disease test for patients previously diagnosed with cancer. Tailored to each patient using their own tumour tissue, the test analyses circulating tumour DNA to detect and measure residual cancer, identify potential recurrence earlier than conventional methods, and support treatment decisions.

Developed in-house, its ultra-sensitive approach is designed to track tumour-specific signals, instead of relying on a generic set of mutations.

OncoTrack MRD enables clinicians to monitor relapse throughout the course of cancer care through a simple, repeatable blood test that can be performed multiple times a year, as clinically appropriate. By tracking changes in tumour DNA over time, it provides insights into residual disease and treatment response and can help identify the risk of recurrence earlier. With convenient home sample collection and nationwide availability, OncoTrack MRD enables accessible, longitudinal monitoring for patients across India.